Valley Cottage, NY -- (SBWIRE) -- 01/12/2019 -- Scleroderma is a umbrella term for a group of autoimmune diseases resulting in changes in blood vessels, skin, muscles, and other organs. The symptoms of Scleroderma include thickened and stiff skin, lethargy, and poor blood flow to extremities of the limbs such as fingers and toes on exposure to cold. Scleroderma can also result in deposition of calcium deposits, Raynaud's syndrome, and esophageal problems.

Scleroderma Treatment Market: Dynamics

The increasing incidence and screening rates of Scleroderma is the prime driver of the Scleroderma market. The prevalence of Scleroderma in the U.S. accounting for 240 per million and an annual incidence of 19 per million is an indication of large unmet need. The European prevalence of Scleroderma is estimated to be between 10 and 150 per million people, while the annual incidence has been reported to be between 3 and 28 per million people.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8315

The increasing exposure to risk factors such as exposure to silica, aromatic and chlorinated solvents, ketones, welding fumes and the development of advanced high sensitive and selective skin biopsy and blood tests is driving a large market growth. The high recurrence and expanse of the disease to systemic resulting in death due to heart, lung, and gastrointestinal complications is driving a large market owing to low elasticity of demand. The incidence of systemic Scleroderma is estimated to be around 3 for every 100,000 people per year. The growing geriatric population is another driver of the market as Scleroderma most often begins in middle age.

However, factors restraining the Scleroderma treatment market include lack of curative treatment, poor efficacy and efficiency of present drug regimens, and others.

Scleroderma Treatment Market: Segmentation

The scleroderma treatment market is segmented on the basis of drug class, types, distribution channel and region.

Based on drug class, the global scleroderma treatment market is segmented into:

Anti-inflammatory agents
Immunosuppressive agents
Vascular agents
Anti-fibrotic agents
Others
Based on types, the global scleroderma treatment market is segmented into:

Localized
Systemic
Based on distribution channel, the global scleroderma treatment market is segmented into:

Institutional Sales
Retail Sales
Online Sales

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-8315

Scleroderma Treatment Market: Overview

Based on regions, the global scleroderma treatment market is classified into North America, Latin America, Europe, CIS & Russia, Japan, Asia-Pacific excluding Japan (APEJ) and the Middle East & Africa (MEA). North America is expected to account for the largest share in the global Scleroderma treatment market owing to growth in the income of women, large investments by pharmaceutical companies and the huge potential of the market.

The scleroderma Treatment markets in Europe is expected to be led by Germany, France and the UK. China and India are expected to drive the lion's share in the Asia Pacific Scleroderma treatment market.

The Middle East and Africa Scleroderma Treatment market is expected to be driven by the gulf economies of Saudi Arabia, Kuwait and Qatar. However, poor per capita income of African countries is likely to hamper the Scleroderma Treatment market growth in this region.

Scleroderma Treatment Market: Key Players

Some of the major players in the global Scleroderma Treatment market are Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., Sanofi, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals Holdings, Inc., Actelion Pharmaceuticals, Inc.,, Bayer AG, Cytori Therapeutics, Inc., and others.

Read Report Overview @ https://www.futuremarketinsights.com/reports/scleroderma-treatment-market